1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
622E16770A531574D00258D500032C63F
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/22E16770A531574D00258D500032C63F?OpenDocument
18
19OpenDocument
2018.97.14.83
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Patient Advocacy

Document Excerpt: Patient-Focused Impact: Linking Medical Activities to Outcomes

DB Image

ID: MD-1002


Features:

9 Info Graphics

15 Data Graphics

380+ Metrics

5 Narratives


Pages/Slides: 4


Published: 2025


Delivery Format: Online PDF Document


 

License Options:


Download FREE Excerpt

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
To download this excerpt, click "Download Free Excerpt".

To return to the study abstract to purchase the full study -
click here

This excerpt includes research findings and metrics from document #5902 “Patient-Focused Impact: Linking Medical Activities to Outcomes”.

Industries Profiled:
Pharmaceutical; Biopharmaceutical; Biotech; Manufacturing; Consumer Products; Diagnostic; Medical Device; Health Care; Clinical Research; Laboratories


Companies Profiled:
AbbVie; ADVANZ PHARMA; Alnylam Pharmaceuticals; argenx; Arrowhead Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Biogen; Boehringer Ingelheim; Cytokinetics; Eva Pharma; Ferring Pharmaceuticals; Grünenthal; Insmed; Jazz Pharmaceuticals; Merck; Otsuka; Sanofi; Vertex Pharmaceuticals; Xenon Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.